CompletedNot applicableNCT04568967
TB-CAPT EXULTANT - HIV
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
- Principal Investigator
- Alberto García-Basteiro, MD, M.DBarcelona Institute for Global Health
- Intervention
- Concentrated urine with Xpert Ultra(diagnostic_test)
- Enrollment
- 1172 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (4)
- Centro de Investigação em Saúde de Manhiça-Fundação, Manhiça, Vila Da Manhiça, Mozambique
- Instituto Nacional de Saúde (INS), Maputo, Mozambique
- Ifakara Health Institute (IHI), Bagamoyo, Tanzania
- National Institute of Medical Research (NIMR), Mbeya, Tanzania
Collaborators
Ludwig-Maximilians - University of Munich · Instituto Nacional de Saúde, Mozambique · Centro de Investigação em Saúde de Manhiça · National Institute for Medical Research, Tanzania · Ifakara Health Institute · Ospedale San Raffaele · Swiss Tropical & Public Health Institute · African Society for Laboratory Medicine · Heidelberg University · Barcelona Institute for Global Health
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04568967 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine